Proxy Votes Now

Home › Funds › Guggenheim › Biotechnology Fund

Biotechnology Fund (RYBOX) proxy voting record 2025-2026

Fund family: Guggenheim · Filed by RYDEX SERIES FUNDS (CIK 899148) · SEC series S000003802

Share classes and tickers: RYBOX (C000010596), RYCFX (C000010597), RYOAX (C000010595), RYOIX (C000010594)

“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 611 with, 7 against, 0 abstentions (not counted as with management). Shareholder proposals: 3 FOR, 4 AGAINST, 0 abstained, by the filing’s own vote-source field.

Compared with Guggenheim as a whole

The same two figures as Guggenheim’s manager page (148,731 ballot items across 82 funds and accounts), counted the same way for this fund.

2025-2026This fundItemsGuggenheimItems
Voted FOR the board's own proposals (directors, pay, auditor, capital, transactions, fund matters)81.6%58091.0%135,765
Backed environmental and social shareholder proposals at US companiesn/a25.8%1,981

Where this fund voted differently from most Guggenheim funds

Each ballot item this fund voted is set against the votes of the other Guggenheim funds and accounts on the same item (same meeting, same proposal): “most funds” is a strict majority of at least three of them, FOR against AGAINST, WITHHOLD or ABSTAIN, with split votes and items not voted left out. Funds in one family can follow separate voting policies, for example ESG funds, sub-advised funds and funds using pass-through voting.

Voted the same way as most Guggenheim funds on all 495 items where a comparison was possible.

Votes against management by sector

The same votes as “with management” above, by the sector of the company voted on. 89.5% of this fund’s 618 such votes could be given a sector; the other 65 (10.5%) are at companies without one and are not in the table.

SectorVotesAgainst managementShare
Health Care55371.3%

What it voted on

Ballot items by the category the filing put first; “against management” as above.
Proposal typeItemsAgainst management
Director Elections3650
Say-on-Pay730
Audit-related720
Compensation460
Corporate Governance355
Capital Structure250
Extraordinary Transactions50
Other Social Issues21
Environment or Climate11

Its largest holdings’ meetings

Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.

CompanyMeetingEst. positionItemsAgainst mgmt
Moderna, Inc.May 6, 2026$13M50
AbbVie Inc.May 8, 2026$13M81
Moderna, Inc.November 12, 2025$10M20
Amgen Inc.May 19, 2026$9M151
Gilead Sciences, Inc.April 30, 2026$8M153
Vertex Pharmaceuticals IncorporatedMay 13, 2026$6M141
Regeneron Pharmaceuticals, Inc.June 12, 2026$5M70
Illumina, Inc.May 21, 2026$4M110

Notable votes against management

MeetingCompanyProposalFundMgmt
May 8, 2026AbbVie Inc.Stockholder Proposal - to Adopt a Policy to Require an Independent Chair Shareholder proposalForAgainst
May 19, 2026Amgen Inc.Stockholder proposal to require an independent board chairman. Shareholder proposalAgainstFor
April 30, 2026Gilead Sciences, Inc.To vote on a stockholder proposal requesting an independent Board Chair policy, if properly presented at the Annual Meeting. Shareholder proposalAgainstFor
April 30, 2026Gilead Sciences, Inc.To vote on a stockholder proposal requesting a report on the impact of extended patent exclusivities on patient access, if properly presented at the Annual Meeting. Shareholder proposalAgainstFor
May 13, 2026Vertex Pharmaceuticals IncorporatedShareholder proposal, if properly presented at the meeting, regarding shareholder right to act by written consent. Shareholder proposalForAgainst
May 15, 2026Medpace Holdings, Inc.Stockholder proposal regarding giving shareholders an ability to call for a special shareholder meeting, if properly presented at the meeting. Shareholder proposalForAgainst

Contested meetings

Meetings with a proxy contest or competing nominees (1 in 2025-2026), and how the fund voted the items on its ballot.

Funds that vote the same way

These funds reported the same votes as Biotechnology Fund in the latest season, so they share this page:

Search this fund’s votes by company

624 ballot items at 75 meetings in 2025-2026. Download all votes (CSV)

Recent notable votes

Recent votes against management’s recommendation at large companies.

About this fund’s record

In the 2025-2026 proxy season, Biotechnology Fund (RYBOX) voted at 75 shareholder meetings of 72 companies, on 624 ballot items in all. Where management made a recommendation, the fund followed it on 98.9% of the items and voted against it 7 times. Its most frequent area of disagreement was corporate governance (5 of its votes against management). It voted on 7 shareholder proposals. It voted FOR the board's own proposals less often than Guggenheim's funds as a whole (81.6% against 91.0%). It voted the same way as most Guggenheim funds on every item where a comparison was possible. 1 of its meetings was contested.

About this page

Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026; the family figures are those of Guggenheim’s manager page. The interactive database shows the same votes company by company, with every other fund that voted.